SGO 2023

Conference Coverage

Dostarlimab Plus Chemo Deemed New Standard Care for Endometrial Cancer

Adding dostarlimab to chemotherapy can improve outcomes in patients with primary advanced or recurrent endometrial cancer, a phase 3 trial suggests.

Durvalumab, Tremelimumab, and Chemo Deemed Active in Advanced Ovarian Cancer

The combination of durvalumab, tremelimumab, and chemotherapy can produce durable responses in patients with newly diagnosed, advanced-stage epithelial ovarian cancer, a phase 2 trial suggests.

Adavosertib Appears Active but Toxic in Advanced Uterine Cancer

Adavosertib is active but not well tolerated in patients with recurrent or persistent uterine serous carcinoma, a phase 2 study suggests.

Pembrolizumab Improves PFS in Advanced, Recurrent Endometrial Cancer

Adding pembrolizumab to chemotherapy improves progression-free survival in advanced or recurrent endometrial cancer, a phase 3 trial suggests.

Adding Anlotinib to Pembrolizumab Improves PFS in Ovarian Cancer

Anlotinib enhances the efficacy of pembrolizumab in patients with recurrent or refractory high-grade serous ovarian cancer, a phase 2 study suggests.

No Difference Between Chemoradiotherapy and Chemo Alone in Endometrial Cancer

Chemoradiotherapy does not improve overall survival, compared with chemotherapy alone, in patients with locally advanced endometrial cancer, a phase 3 trial suggests.

Toripalimab, Bevacizumab, and Chemo Deemed Effective in Advanced Cervical Cancer

The combination of toripalimab, bevacizumab, and platinum-based chemotherapy appears safe and effective for patients with advanced cervical cancer.

Clinical Trial Participation Linked to Longer OS in Platinum-Resistant Ovarian Cancer

Patients with platinum-resistant epithelial ovarian cancer may have better overall survival if they enroll on a clinical trial than if they receive standard care.

54 Million US Women May Lack Access to a Gynecologic Oncologist 

The number of gynecologic oncologists in the US has grown in recent years, but many patients still lack access to a gynecologic oncologist.

Reimbursement for Gynecologic Oncology Procedures Has Not Kept Up With Inflation

Physician reimbursement rates for gynecologic oncology procedures have increased in recent years but have not kept up with inflation, a study suggests.

Gemcitabine Plus Cisplatin and IMRT Produces Complete Responses in Vulvar Cancer

The combination of gemcitabine, cisplatin, and IMRT appears effective in patients with locally advanced, unresectable vulvar cancer.

Cryocompression May Reduce Peripheral Neuropathy in Gynecologic Cancer

Cryocompression can reduce subjective peripheral neuropathy in patients with gynecologic cancer undergoing chemotherapy, a study suggests.

Ribociclib Plus Letrozole Yields Responses in Recurrent Ovarian Cancer

Ribociclib plus letrozole elicits responses in patients with recurrent low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum, a phase 2 study suggests.